Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1/2 1

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Head & Neck 3CNS 1

Conditions

Head and Neck Neoplasms 408Squamous Cell Carcinoma of Head and Neck 326Thyroid Neoplasms 104Carcinoma, Non-Small-Cell Lung 85Neoplasms 66Oropharyngeal Neoplasms 59Carcinoma, Squamous Cell 59Melanoma 56Lung Neoplasms 47Neoplasm Metastasis 44Mouth Neoplasms 43Breast Neoplasms 42Laryngeal Neoplasms 39Thyroid Cancer, Papillary 36Salivary Gland Neoplasms 35Colorectal Neoplasms 35Ovarian Neoplasms 33Carcinoma, Renal Cell 33Esophageal Neoplasms 32Urinary Bladder Neoplasms 30Stomach Neoplasms 30Tongue Neoplasms 28Nasopharyngeal Neoplasms 28Uterine Cervical Neoplasms 27Carcinoma 27Pancreatic Neoplasms 26Triple Negative Breast Neoplasms 24Sarcoma 24Carcinoma, Medullary 24Recurrence 22

Interventions

pembrolizumab 1Radiotherapy 1Hydroxyurea 1Fluorouracil 1Cetuximab 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Has results × Nose Neoplasms × Head & Neck × Clear all
NCT03769467 2024-11-14

Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC)

Atara Biotherapeutics

Phase 1/2 Terminated
12 enrolled 8 charts
Head & Neck

Nasopharyngeal Carcinoma, Carcinoma, Head and Neck Neoplasms, Stomatognathic Diseases, Nasopharyngeal Diseases, Nasopharyngeal Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Nose Neoplasms, Otorhinolaryngologic Diseases, Otorhinolaryngologic Neoplasms, Pharyngeal Diseases, Pharyngeal Neoplasms, Epstein-Barr Virus Infections

NCT02578641 2023-06-28

VANCE

Tessa Therapeutics

Phase 3 Completed
330 enrolled 18 charts
Head & Neck

Nasopharyngeal Carcinoma, Head and Neck Neoplasms, Nasopharyngeal Neoplasms, Nose Neoplasms, Epstein-Barr Virus Infections

NCT00462735 2018-03-13

Fluorouracil, Hydroxyurea, Cetuximab and Twice-daily Intensity Radiation Therapy for Advanced Head and Neck Cancer

Icahn School of Medicine at Mount Sinai

Phase 2 Completed
33 enrolled 15 charts
Head & Neck

Head and Neck Neoplasms, Laryngeal Neoplasms, Nose Neoplasms, Paranasal Sinus Neoplasms, Pharyngeal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡